跳转至内容
Merck

SML2044

Sigma-Aldrich

DMAT

≥98% (HPLC)

别名:

CK2 Inhibitor II, 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole, 4,5,6,7-Tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine, 4,5,6,7-Tetrabromo-N,N-dimethyl-1H-benzo[d]imidazol-2-amine, DMAT

登录查看公司和协议定价

选择尺寸

5 MG
$114.00
25 MG
$468.00

$114.00


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
5 MG
$114.00
25 MG
$468.00

About This Item

经验公式(希尔记法):
C9H7Br4N3
分子量:
476.79
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

$114.00


请联系客服了解存货情况

获取大包装报价

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

运输

wet ice

储存温度

−20°C

SMILES字符串

CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1

InChI

1S/C9H7Br4N3/c1-16(2)9-14-7-5(12)3(10)4(11)6(13)8(7)15-9/h1-2H3,(H,14,15)

InChI key

SLPJGDQJLTYWCI-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

DMAT has been used as a casein kinase 2 (CK2) inhibitor:
  • to study its effects on parasite multiplication in a [3H]-hypoxanthine incorporation assay[1]
  • to study its effects on the intracellular response in prostate cancer cells[2]
  • to study its effects on cell division cycle 25C (cdc25C) phosphatase levels in prostate cancer cells[3]

生化/生理作用

Casein kinase II inhibitor II (Ck2 Inhibitor II) is a ATP competitive inhibitor of casein kinase II.
Casein kinase II inhibitor II (Ck2 Inhibitor II) is a high affinity ATP-competitive inhibitor of casein kinase II. Ck2 Inhibitor II inhibits CK2 in rat liver with 1,300-fold greater selectivity for CK2 than for CK1 (IC50 = 140 nM and >200 μM respectively). Ki = 40 nM; In Jurkat human T-cell leukemia cells, Ck2 Inhibitor II does not display side effects on mitochondria polarization at concentrations up to 10 μM; Ck2 Inhibitor II is useful for in vivo studies due to cell permeability and high efficacy in cultured cells and has implications in research and treatment of neoplasia and infective diseases, in which CK2 plays a role and is highly active constitutively.
DMAT is an ATP-competitive (Ki = 40 nM) casein kinase 2 (CK2) inhibitor (IC50 = 140 nM; rat liver CK2, [ATP] = 20 nM) with greatly improved potency and selectivity than its structure analog TBB. With the exception of DYRK1a (IC50 = 120 nM), DMAT is reported to exhibit no CK1 inhibitiory potency up to 200 μM (50% inhibition by 29 μM TBB) and little or no activity against a panel of 32 other protein kinases, nor PI3K α and γ. When tested in Jurkat cultures, DMAT is shown to be a superior apoptosis inducer than TBB (DC50 = 2.7 μM/DMAT vs. 17 μM/TBB).

注意

Air sensitive

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mario A Pagano et al.
Journal of medicinal chemistry, 47(25), 6239-6247 (2004-11-30)
Casein kinase 2 (CK2) is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and infective diseases. Thus, CK2 inhibitors designed to dissect the signaling pathways affected
Mario A Pagano et al.
Biochemical and biophysical research communications, 321(4), 1040-1044 (2004-09-11)
Protein kinase CK2 is a highly pleiotropic enzyme whose high constitutive activity is suspected to be instrumental to the enhancement of the tumour phenotype and to the propagation of infectious diseases. Here we describe a novel compound, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), which
Carolin C Schneider et al.
Oncology reports, 21(6), 1593-1597 (2009-05-09)
Elevated levels of protein kinase CK2 were found in tumour cells compared to normal cells. Thus, inhibition of CK2 kinase activity seems to be an attractive method to stop growth of cancer cells. Two drugs, namely tetrabromobenzotriazole, TBB, and 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
Claudia Götz et al.
Biochimica et biophysica acta, 1820(7), 970-977 (2012-03-06)
Abnormally high activity of protein kinase CK2 is linked to various diseases including cancer. Therefore, the inhibition of CK2 is a promising therapeutic strategy to fight this disease. We screened a library of synthetic molecules concerning their capacity to inhibit
Konrad Kubiński et al.
Molecular and cellular biochemistry, 426(1-2), 195-203 (2016-12-03)
Benzimidazole derivatives of 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) comprise the important class of protein kinase CK2 inhibitors. Depending on the structure, benzimidazoles inhibit CK2 with different selectivity and potency. Besides CK2, the compounds can inhibit, with similar activity, other classical eukaryotic protein

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门